Concepedia

Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2)

R. Kristeleit, Ronnie Shapira‐Frommer, Ana Oaknin, Judith Balmañà, Isabelle Laure Ray-Coquard, Susan M. Domchek, Anna V. Tinker, Cesar M. Castro, Stephen Welch, Andrés Poveda,

Annals of Oncology · 2016 · 24 citations · 0 references

DOIFull text

Open access

Concepts